Four molecules possessing a pyridazinone scaffold, namely compounds 3a, 3c [28], 4aa and 4ba [29], derived from the first two molecules, were chosen as therapeutic candidates for their ability to inhibit PDE4, to be used against primary osteosarcoma. This evidence concerns the gene PDE4A and osteosarcoma.